RANI

Rani Therapeutics Holdings, Inc. - 10-Q Summary (Q3 2025)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing the RaniPill, a drug-agnostic oral delivery platform designed to administer biologics and drugs orally. The company operates in one segment and is headquartered in San Jose, California. As of the reporting date, the company had no approved commercial products and generated minimal revenue from evaluation services.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 38.5% in Q3 2025 compared to Q3 2024, driven by a 47.8% reduction in R&D expenses and a 28.3% reduction in G&A expenses. Management attributed this to lower headcount, reduced compensation costs, and a temporary pause in certain R&D programs.
• Liquidity Position: Marketable securities dropped from $23.9 million at year-end 2024 to $0 at September 30, 2025, as the company utilized these assets to fund operations. Cash and cash equivalents remained relatively stable at $4.1 million.
• Revenue Recognition: The company recognized $0.2 million in contract revenue for the nine months ended September 30, 2025, related to evaluation services for Chugai Pharmaceutical Co., Ltd. No revenue was recognized in the comparable 2024 period.
• Debt Repayment: The company repaid $11.3 million of debt during the nine months ended September 30, 2025.

Guidance, Outlook, and Subsequent Events

Going Concern: As of September 30, 2025, the company had an accumulated deficit of $122.3 million and negative operating cash flows, raising substantial doubt about its ability to continue as a going concern. However, management states this doubt has been alleviated by significant financing and collaboration activities occurring in October 2025.

Subsequent Events (October 2025):

• Private Placement: The company closed a private placement raising approximately $60.3 million (gross proceeds), including the conversion of $6.0 million of existing debt into equity.
• Chugai Collaboration: Entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. for the development of an oral hemophilia product. The deal includes a $10.0 million upfront payment, up to $18.0 million in technology transfer milestones, $57.0 million in development milestones, and up to $100.0 million in sales-based milestones.
• Warrant Exercises: An equity investor exercised Series D warrants for $4.5 million in cash proceeds.
• Nasdaq Compliance: The company regained compliance with Nasdaq listing requirements regarding minimum bid price and market value of listed securities in November 2025.

Risks: The company faces risks related to the success of the Chugai collaboration, the ability to raise additional capital, and potential trade tariffs affecting supply chains. There is no guarantee that future financing will be available on favorable terms.

Investor Verification Checklist

• Verify the receipt of the $10.0 million upfront payment from the Chugai Collaboration and License Agreement.
• Confirm the closing details and net proceeds of the October 2025 Private Placement after deducting placement agent fees and expenses.
• Monitor the status of the $13.5 million current debt obligation and the terms of the debt conversion.
• Review the timeline for the initiation of the Phase 1 clinical trial for RT-114 (oral GLP-1/GLP-2 agonist), targeted for late 2025.
• Assess the impact of the "temporary pause" on R&D programs and the timeline for resumption.
• Track the company's compliance with Nasdaq listing standards to ensure continued trading status.